Provider Letter OHCA 2017-04 Prior Authorization of
Medications Used to Treat Skin Cancer
Effective April 10, 2017, the
Oklahoma Health Care Authority (OHCA) will require a prior authorization (PA)
for the following medications: Odomzo® (Sonidegib), Erivedge® (Vismodegib),
Keytruda® (Pembrolizumab), Opdivo® (Nivolumab), Yervoy® (Ipilimumab), Tafinlar®
(Dabrafenib), Zelboraf® (Vemurafenib), Cotellic® (Cobimetinib), Mekinist®
(Trametinib), Imlygic® (Talimogene Laherparepvec).
If a SoonerCare member is
currently on therapy with one of these medications, the medication will be
“grandfathered.” Based on past claims, PA will be automatic for drugs obtained
through the pharmacy claim system.
Please view the Provider Letter
in its entirety here: Provider Letter 2017-04.
Submit all comments by close of business, April
10, 2017, via the comment box below.